Clinical trial
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
NCT00014430 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00014430 |
|---|---|
| Title | Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer |
| Official title | Phase I Clinical Trial Of Vinorelbine (Navelbine) And Trastuzumab (Herceptin) In Patients With Carcinoma Of The Breast Or Non-Small Cell Lung Cancer And HER-2/NEU Overexpression |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, vinorelbine ditartrate |
| Enrollment | 13 |
| Start date | Nov 1, 1999 |
| Primary completion | Sep 1, 2002 |
| First posted | Feb 16, 2004 |
| Last update posted | Mar 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: